Gynecology Outpatient Department, Chief Physician. Born in Hunan, Dr. Cao Aie graduated from Nanchang University. For over 30 years since graduation, she has been dedicated to clinical work in gynecology and obstetrics. She has furthered her studies at Xiangya Hospital Central South University, the Department of Gynecology and Obstetrics at Peking Union Medical College Hospital, and Wayne State University in the United States.

She specializes in surgical treatments for both benign and malignant gynecological tumors, including cervical cancer, endometrial cancer, ovarian cancer, uterine fibroids, ovarian tumors, endometriosis, uterine prolapse, and intrauterine adhesions. She has extensive experience in chemotherapy, targeted therapy, and immunotherapy for gynecological malignancies such as cervical cancer, endometrial cancer, ovarian cancer, and vulvar cancer. She has successfully performed over ten thousand open surgeries, as well as minimally invasive procedures including laparoscopy, hysteroscopy, and vaginal surgery.

Experimental study on fertility preservation operation for ovarian epithelial carcinoma

I. Vice Chairman of the Gynecologic Oncology Professional Committee, Hainan Anti-Cancer Association

II. Standing member of the Obstetricians and Gynecologists Branch of Hainan Provincial Physicians Association

III. Standing member of Minimally Invasive Gynecology Specialized Committee of Hainan Medical Association

IV. Standing member of Cervical Cancer Prevention and Treatment Specialized Committee of Hainan Maternal and Child Health Association

V. Member of the Sixth Committee of Medical Genetics Branch of Hainan Medical Association

VI. Member of Maternal-Fetal Medicine Group, Obstetricians and Gynecologists Branch, Hainan Provincial Physicians Association

1.Expression and Clinical Significance of Ubiquitin-specific Protease I and Karyopherin a-2 in Endometriosis Patients, China Journal of Eugenics and Genetics, Volume 30, 2022.  
2.Study on the Mechanism of Regulation of Proliferation and Apoptosis of Cervical Cancer Cells by Targeting mid-506-5P with Inc RNA FOXD2-ASI", Chinese Journal of Cancer Biotherapy, Vol. 26, Issue 10. 
3.2020 Research Project of Hainan Provincial Health Department (in progress): Study on the Application of Low Molecular Weight Heparin Sodium in Patients with Recurrent Abortion. 
4.Also participated in the ongoing national multicenter clinical studies, including Multicenter Screening and Early Diagnosis of Endometrial Cancer in High Risk Groups and Study of Cervical Cytology DNA Early Basification for Endometrial Cancer Screening.